News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
226,830 Results
Type
Article (5139)
Company Profile (18)
Press Release (221673)
Multimedia
Podcasts (1)
Webinars (4)
Section
Business (82440)
Career Advice (462)
Deals (15068)
Drug Delivery (8)
Drug Development (19406)
Employer Resources (30)
FDA (3698)
Job Trends (3914)
News (120683)
Policy (7553)
Tag
Academia (313)
Accelerated approval (2)
Adcomms (3)
Allergies (9)
Alliances (14844)
ALS (21)
Alzheimer's disease (265)
Antibody-drug conjugate (ADC) (11)
Approvals (3716)
Artificial intelligence (45)
Autoimmune disease (3)
Automation (3)
Bankruptcy (97)
Best Places to Work (2873)
Biosimilars (11)
Biotechnology (22)
Bladder cancer (11)
Brain cancer (7)
Breast cancer (48)
Cancer (465)
Cardiovascular disease (24)
Career advice (394)
Career pathing (3)
CAR-T (33)
Cell therapy (108)
Cervical cancer (2)
Clinical research (16311)
Collaboration (180)
Compensation (183)
Complete response letters (2)
COVID-19 (307)
CRISPR (8)
C-suite (114)
Cystic fibrosis (16)
Data (540)
Depression (7)
Diabetes (43)
Diagnostics (2049)
Digital health (3)
Diversity, equity & inclusion (12)
Drug discovery (15)
Drug pricing (6)
Drug shortages (1)
Duchenne muscular dystrophy (13)
Earnings (41114)
Editorial (2)
Employer branding (6)
Employer resources (31)
Events (38036)
Executive appointments (324)
FDA (4012)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (3)
Funding (196)
Gene editing (16)
Generative AI (2)
Gene therapy (61)
GLP-1 (111)
Government (416)
Guidances (63)
Healthcare (5074)
Huntington's disease (1)
IgA nephropathy (4)
Immunology and inflammation (15)
Indications (6)
Infectious disease (323)
Inflammatory bowel disease (24)
Inflation Reduction Act (2)
Influenza (3)
Intellectual property (16)
Interviews (53)
IPO (7836)
IRA (3)
Job creations (1124)
Job search strategy (361)
Kidney cancer (7)
Labor market (5)
Layoffs (104)
Leadership (5)
Legal (2334)
Liver cancer (18)
Lung cancer (54)
Lymphoma (33)
Management (10)
Manufacturing (53)
MASH (30)
Medical device (3874)
Medtech (3875)
Mergers & acquisitions (7448)
Metabolic disorders (127)
Multiple sclerosis (11)
NASH (6)
Neurodegenerative disease (15)
Neuropsychiatric disorders (1)
Neuroscience (373)
NextGen: Class of 2025 (1688)
Non-profit (743)
Now hiring (3)
Obesity (54)
Opinion (30)
Ovarian cancer (17)
Pain (14)
Pancreatic cancer (14)
Parkinson's disease (29)
Partnered (4)
Patents (23)
Patient recruitment (33)
Peanut (5)
People (24730)
Pharmaceutical (5)
Pharmacy benefit managers (2)
Phase I (4884)
Phase II (7106)
Phase III (5627)
Pipeline (645)
Policy (10)
Postmarket research (633)
Preclinical (1908)
Press Release (66)
Prostate cancer (27)
Psychedelics (3)
Radiopharmaceuticals (105)
Rare diseases (78)
Real estate (1875)
Recruiting (8)
Regulatory (5183)
Reports (14)
Research institute (312)
Resumes & cover letters (68)
Rett syndrome (4)
Schizophrenia (21)
Series A (28)
Series B (26)
Sickle cell disease (7)
Special edition (1)
Spinal muscular atrophy (29)
Sponsored (4)
Startups (1018)
Stomach cancer (1)
Supply chain (10)
Tariffs (5)
The Weekly (1)
Vaccines (38)
Venture capitalists (2)
Weight loss (22)
Women's health (1)
Date
Today (92)
Last 7 days (337)
Last 30 days (897)
Last 365 days (9881)
2025 (3549)
2024 (11125)
2023 (13267)
2022 (18764)
2021 (19805)
2020 (18325)
2019 (13274)
2018 (10252)
2017 (10044)
2016 (9198)
2015 (12171)
2014 (9640)
2013 (7753)
2012 (8383)
2011 (8853)
2010 (8682)
Location
Africa (184)
Alabama (13)
Alaska (2)
Arizona (61)
Arkansas (1)
Asia (11515)
Australia (1619)
California (2078)
Canada (740)
China (74)
Colorado (85)
Connecticut (101)
Delaware (32)
Europe (24726)
Florida (301)
Georgia (34)
Idaho (23)
Illinois (120)
India (7)
Indiana (66)
Iowa (2)
Japan (78)
Kansas (24)
Kentucky (12)
Louisiana (5)
Maine (40)
Maryland (235)
Massachusetts (1667)
Michigan (87)
Minnesota (143)
Mississippi (1)
Missouri (23)
Montana (16)
Nebraska (12)
Nevada (26)
New Hampshire (16)
New Jersey (599)
New Mexico (5)
New York (499)
North Carolina (340)
North Dakota (3)
Northern California (1001)
Ohio (62)
Oklahoma (5)
Oregon (4)
Pennsylvania (365)
Puerto Rico (1)
Rhode Island (14)
South America (277)
South Carolina (7)
Southern California (747)
Tennessee (42)
Texas (244)
United States (7498)
Utah (64)
Virginia (48)
Washington D.C. (11)
Washington State (183)
West Virginia (2)
Wisconsin (26)
226,830 Results for "neurogen corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Gene therapy
Neurogene Details Gene Therapy Complication, Sending Shares Plummeting Again
Neurogene’s shares fell by 36% as the market opened Monday morning following news that a patient experienced systemic hyperinflammatory syndrome in a Phase I/II clinical trial of Rett syndrome gene therapy NGN-401.
November 18, 2024
·
2 min read
·
Annalee Armstrong
Pipeline
Neurogene Drops Batten Gene Therapy Program
After failing to receive the RMAT designation from the FDA for its early-stage Batten disease gene therapy, Neurogene tells investors that it’s evaluating options for the program.
November 19, 2024
·
2 min read
·
Kate Goodwin
Press Releases
Neurogene to Participate in Upcoming Conferences
February 24, 2025
·
1 min read
Gene therapy
Patient Death in Rett Syndrome Trial Forces Neurogene to Drop High-Dose Arm
Despite the death, the FDA has allowed Neurogene to forge ahead with the Phase I/II Rett syndrome trial, but using only the lower 1E15 vg dose of its investigational gene therapy NGN-401.
November 22, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Neurogene Announces Addition to Russell 3000® Index
Neurogene Inc. today announced that Neurogene will be added to the Russell 3000 ® Index, effective at the open of U.S. equity markets today, Monday, July 1, 2024.
July 1, 2024
·
5 min read
Press Releases
Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting
April 28, 2025
·
5 min read
Pharm Country
Neurogene to Participate in Upcoming Conferences
Neurogene Inc. today announced that Company management will participate in the following conferences.
June 5, 2024
·
2 min read
Press Releases
Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates
March 24, 2025
·
10 min read
Press Releases
Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome
April 3, 2025
·
8 min read
Business
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
Neurogene Inc., a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, announced first quarter 2024 financial results and highlighted recent corporate updates.
May 10, 2024
·
10 min read
1 of 22,683
Next
